Rajiv Patni - Jun 12, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role: EVP, Chief R&D Officer
Signature: /s/ Tracy Herson, attorney-in-fact
Stock symbol: RETA
Transactions as of: Jun 12, 2023
Transactions value $: $0
Form type: 4
Date filed: 6/14/2023, 04:26 PM
Next filing: Sep 26, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$0	+45K		$0.00	45K	Jun 12, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Employee Stock Option (right-to-buy)	Award	$0	+90K		$0.00	90K	Jun 12, 2023	Class A common stock	90K	$99.12	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent Restricted Stock Units, which vest as to 11,250 shares on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date.
F2	The option, representing a right to purchase a total of 90,000 Class A shares, become exercisable as to 22,500 on June 12, 2024, with the remainder to vest in twelve equal quarterly installments thereafter, subject to continued service through each vesting date.